NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies develops drug candidates and delivery methods focused on intracranial malignancies, including primary brain cancers and cancers that have spread to the brain. Its two lead candidates are NEO100, purified perillyl alcohol administered intranasally and being studied for brain tumors, and NEO212, an oral compound combining temozolomide with perillyl alcohol that is in clinical testing for primary and secondary brain tumors. NeOnc is also developing intranasal NEO212 for brain metastases and investigating NEO100 as a drug-delivery vehicle and in other delivery approaches. The company has acquired intellectual property covering AI-driven drug discovery, 3D bioprinting and quantum molecular modeling. None of its candidates is approved for sale, and it has no commercial products or sales and marketing infrastructure. NeOnc is headquartered in Calabasas, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
PepGen (PEPG) surged 114% after positive Phase 2 data for its muscular dystrophy treatment. Zura Bio (ZURA) rose 15% despite discontinuing a clinical program. NeOnc (NTHI) gained 13% following CEO share purchases. Senseonics (SENS) advanced 12% after raising its revenue outlook on strong Q3 growth.
Heshmatpour Amir F (CEO, President) purchased 10,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $3.86 on 2026-11-09.
Heshmatpour Amir F (CEO, President) purchased 70,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.29 ($3.17–$3.39, $0.23M total) across 2 trades over 2026-11-05 to 2026-11-06.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning NTHI (NEONC TECHNOLOGIES HOLDINGS, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent NTHI coverage spans financial news, earnings and insider activity.
In the last 30 days, NTHI insiders filed 3 SEC Form 4 transactions — 3 purchases ($269K) and no sales. The most active reporter was Heshmatpour Amir F, CEO, President, with 3 filings.
Insider buying suggests confidence in upcoming data, likely encouraging short‑term buying.
Minor insider purchase suggests confidence but size is too small to move the stock.
Insider buying signals confidence and may create modest upward pressure on the stock.
Positive trial data and stronger balance sheet may lift the stock.
The company posted zero revenue and a modest loss, indicating continued cash burn and limited near‑term upside.
AlphAI scores every news story that mentions NTHI with an AI model for sentiment and relevance, and aggregates insider trades from NEONC TECHNOLOGIES HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PepGen (PEPG) surged 114% after positive Phase 2 data for its muscular dystrophy treatment. Zura Bio (ZURA) rose 15% despite discontinuing a clinical program. NeOnc (NTHI) gained 13% following CEO share purchases. Senseonics (SENS) advanced 12% after raising its revenue outlook on strong Q3 growth.
Heshmatpour Amir F (CEO, President) purchased 10,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $3.86 on 2026-11-09.
Heshmatpour Amir F (CEO, President) purchased 70,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.29 ($3.17–$3.39, $0.23M total) across 2 trades over 2026-11-05 to 2026-11-06.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual Meeting on November 13 CALABASAS, Calif., Nov.
NeOnc Technologies reported no revenue and a net loss of $0.28 per share in 3Q 2026, with reduced stock-based compensation and debt costs offset by higher R&D and legal expenses. Clinical trials NEO100-01, NEO100-02, and NEO212 showed progress, with R&D expenses rising to $1.3M.
NeOnc Technologies (NTHI) will present data on its NEO100 and NEO212 programs at the Society for Neuro-Oncology meeting. NEO100 data includes Phase 1/2a study and compassionate use results for recurrent IDH1-mutant astrocytoma. NEO212 data covers Phase 1 safety, pharmacokinetics, and early activity signals in TMZ-resistant recurrent GBM and brain metastases. Both posters are scheduled for November 13, 2026.
NeOnc Technologies (NASDAQ:NTHI) plans a clinical trial for brain cancer treatment NEO100, targeting 500 patients across 30 hospitals in three countries. The trial aims to bypass the blood-brain barrier using intranasal administration. Early observations show significant remission in some patients. The company also advances NEO212, with an FDA meeting scheduled for November 17. High short interest may attract traders.
NeOnc Technologies (NASDAQ: NTHI) plans a 500-patient trial across 30 hospitals in 3 countries for its brain tumor treatment, NEO100. The intranasal delivery method aims to bypass the blood-brain barrier. Early findings and patient experiences highlight the urgency of the research, though results are preliminary.
NeOnc Technologies Holdings (NASDAQ:NTHI) stock cleared key resistance levels on strong volume, with short interest rising. The company signed an MOU with Abu Dhabi's health department and announced two children are receiving its investigational brain tumor treatment, with a third expected. NeOnc also reported early positive clinical observations. The company is scheduled to appear on Fox Business Network.
NeOnc Technologies reported early improvement in a child treated with NEO100 in Abu Dhabi and signed a non-binding MoU with the Department of Health. The MoU focuses on CNS oncology research and potential regional presence. The company will be featured on Health Uncensored.
